Bio-Rad Laboratories PE Ratio 2006-2018 | BIO
Current and historical p/e ratio for Bio-Rad Laboratories (BIO) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Bio-Rad Laboratories PE ratio as of March 22, 2019 is 52.24.
| Bio-Rad Laboratories PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2019-03-22 | 305.59 | 26.23 | |
| 2018-12-31 | 232.22 | $11.65 | 19.93 |
| 2018-09-30 | 312.99 | $41.85 | 7.48 |
| 2018-06-30 | 288.54 | $33.87 | 8.52 |
| 2018-03-31 | 250.08 | $25.17 | 9.94 |
| 2017-12-31 | 238.67 | $3.81 | 62.64 |
| 2017-09-30 | 222.22 | $0.79 | 281.29 |
| 2017-06-30 | 226.31 | $0.50 | 452.62 |
| 2017-03-31 | 199.34 | $0.94 | 212.06 |
| 2016-12-31 | 182.28 | $0.95 | 191.87 |
| 2016-09-30 | 163.81 | $3.33 | 49.19 |
| 2016-06-30 | 143.02 | $3.30 | 43.34 |
| 2016-03-31 | 136.72 | $3.66 | 37.36 |
| 2015-12-31 | 138.66 | $3.85 | 36.02 |
| 2015-09-30 | 134.31 | $3.51 | 38.26 |
| 2015-06-30 | 150.61 | $3.31 | 45.50 |
| 2015-03-31 | 135.18 | $3.43 | 39.41 |
| 2014-12-31 | 120.56 | $3.05 | 39.53 |
| 2014-09-30 | 113.40 | $2.75 | 41.24 |
| 2014-06-30 | 119.71 | $2.11 | 56.73 |
| 2014-03-31 | 128.12 | $2.22 | 57.71 |
| 2013-12-31 | 123.61 | $2.67 | 46.30 |
| 2013-09-30 | 117.56 | $3.28 | 35.84 |
| 2013-06-30 | 112.20 | $5.01 | 22.40 |
| 2013-03-31 | 126.00 | $5.50 | 22.91 |
| 2012-12-31 | 105.05 | $5.91 | 17.77 |
| 2012-09-30 | 106.72 | $6.34 | 16.83 |
| 2012-06-30 | 100.01 | $6.47 | 15.46 |
| 2012-03-31 | 103.69 | $6.19 | 16.75 |
| 2011-12-31 | 96.04 | $6.26 | 15.34 |
| 2011-09-30 | 90.77 | $6.59 | 13.77 |
| 2011-06-30 | 119.36 | $6.57 | 18.17 |
| 2011-03-31 | 120.14 | $6.51 | 18.45 |
| 2010-12-31 | 103.85 | $6.59 | 15.76 |
| 2010-09-30 | 90.51 | $5.53 | 16.37 |
| 2010-06-30 | 86.49 | $5.32 | 16.26 |
| 2010-03-31 | 103.52 | $5.34 | 19.39 |
| 2009-12-31 | 96.46 | $5.20 | 18.55 |
| 2009-09-30 | 91.88 | $3.55 | 25.88 |
| 2009-06-30 | 75.48 | $3.18 | 23.74 |
| 2009-03-31 | 65.90 | $3.39 | 19.44 |
| 2008-12-31 | 75.31 | $3.25 | 23.17 |
| 2008-09-30 | 99.12 | $4.00 | 24.78 |
| 2008-06-30 | 80.89 | $4.02 | 20.12 |
| 2008-03-31 | 88.95 | $3.39 | 26.24 |
| 2007-12-31 | 103.62 | $3.42 | 30.30 |
| 2007-09-30 | 90.50 | $3.58 | 25.28 |
| 2007-06-30 | 75.57 | $3.41 | 22.16 |
| 2007-03-31 | 69.84 | $3.66 | 19.08 |
| 2006-12-31 | 82.52 | $3.83 | 21.55 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $9.156B | $2.290B |
| Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $136.952B | 27.07 |
| Medtronic (MDT) | Ireland | $121.227B | 17.72 |
| Stryker (SYK) | United States | $72.547B | 26.60 |
| Boston Scientific (BSX) | United States | $51.696B | 25.20 |
| Baxter (BAX) | United States | $39.588B | 25.32 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.898B | 16.58 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $17.446B | 0.00 |
| Canopy Growth (CGC) | Canada | $14.852B | 0.00 |
| ResMed (RMD) | United States | $14.350B | 27.21 |
| Aurora Cannabis (ACB) | Canada | $9.141B | 64.50 |
| Hill-Rom Holdings (HRC) | United States | $6.962B | 21.53 |
| Perrigo (PRGO) | Ireland | $6.420B | 10.41 |
| Insulet (PODD) | United States | $5.800B | 1956.80 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $5.092B | 0.00 |
| ICU Medical (ICUI) | United States | $4.698B | 29.24 |
| Haemonetics (HAE) | United States | $4.311B | 38.24 |
| Hutchison China MediTech (HCM) | China | $3.810B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.637B | 0.00 |
| Neogen (NEOG) | United States | $3.108B | 47.74 |
| NuVasive (NUVA) | United States | $2.892B | 25.23 |
| Quidel (QDEL) | United States | $2.514B | 22.68 |
| Aphria (APHA) | $2.385B | 105.89 | |
| National Vision Holdings (EYE) | United States | $2.274B | 44.72 |
| Cardiovascular Systems (CSII) | United States | $1.346B | 966.50 |
| HEXO (HEXO) | $1.340B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.283B | 18.45 |
| VAREX IMAGING (VREX) | United States | $1.275B | 24.96 |
| AtriCure (ATRC) | United States | $1.081B | 0.00 |
| MacroGenics (MGNX) | United States | $0.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.911B | 24.60 |
| Cerus (CERS) | United States | $0.844B | 0.00 |
| PetIQ (PETQ) | United States | $0.831B | 23.77 |
| Omeros (OMER) | United States | $0.828B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.729B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.715B | 21.30 |
| OraSure Technologies (OSUR) | United States | $0.664B | 29.11 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.657B | 22.35 |
| Evolus (EOLS) | United States | $0.655B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.601B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.596B | 28.35 |
| Surmodics (SRDX) | United States | $0.563B | 81.90 |
| Quanterix (QTRX) | United States | $0.518B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.364B | 150.23 |
| Vapotherm (VAPO) | United States | $0.335B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.331B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.328B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.300B | 19.49 |
| Owens & Minor (OMI) | United States | $0.271B | 3.76 |
| Bovie Medical (APYX) | United States | $0.260B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.241B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.238B | 0.00 |
| Zynex (ZYXI) | United States | $0.145B | 15.52 |
| Fonar (FONR) | United States | $0.137B | 7.33 |
| Surface Oncology (SURF) | United States | $0.116B | 0.00 |
| Chimerix (CMRX) | United States | $0.102B | 0.00 |
| Female Health (VERU) | United States | $0.100B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.096B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.091B | 0.00 |
| United-Guardian (UG) | United States | $0.087B | 19.84 |
| CAS Medical Systems (CASM) | United States | $0.072B | 0.00 |
| Neurotrope (NTRP) | United States | $0.065B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.058B | 17.14 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.039B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.035B | 0.00 |
| Senestech (SNES) | United States | $0.029B | 0.00 |
| Myomo (MYO) | United States | $0.022B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.018B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.016B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 15.29 |
